A Comparative Systematic Review of the Optimal CD4 Cell Count Threshold for HIV Treatment Initiation

HIV infection is no longer characterized by high morbidity, rapid progression to AIDS, and death as when the infection was first identified. While anti-retroviral drugs have improved the outcome of AIDS patients, clinical research on the appropriate time to initiate therapy continues to evolve. Opti...

Full description

Saved in:
Bibliographic Details
Main Authors: Babatunde Olubajo, Kathryn Mitchell-Fearon, Oluseye Ogunmoroti
Format: Article
Language:English
Published: Wiley 2014-01-01
Series:Interdisciplinary Perspectives on Infectious Diseases
Online Access:http://dx.doi.org/10.1155/2014/625670
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832545384464908288
author Babatunde Olubajo
Kathryn Mitchell-Fearon
Oluseye Ogunmoroti
author_facet Babatunde Olubajo
Kathryn Mitchell-Fearon
Oluseye Ogunmoroti
author_sort Babatunde Olubajo
collection DOAJ
description HIV infection is no longer characterized by high morbidity, rapid progression to AIDS, and death as when the infection was first identified. While anti-retroviral drugs have improved the outcome of AIDS patients, clinical research on the appropriate time to initiate therapy continues to evolve. Optimal therapy initiation would maximize the benefits of these drugs, while minimizing side effects and drug resistance. Recent 2013 WHO guidelines changed HIV therapy initiation from 350 cells/μL to 500 cells/μL. This systematic review provides an evidence-based comparison of starting treatment at >500 cells/μL with starting treatment at the range between 350 cells/μL and 500 cells/μL. An 11% increase in risk was detected from initiation therapy at the 350–500 cells/μL range (0.37 [0.26, 0.53]), when compared with starting treatment before 500 cells/μL (0.33 [0.22, 0.48]). Most individual study comparisons showed a benefit for starting treatment at 500 cells/μL in comparison with starting at the 350–500 cells/μL range with risks ranging from 19% to 300%, though a number of comparisons were not statistically significant. Overall, the study provides evidence based support for initiating anti retroviral therapy at cell counts >500 cells/μL wherever possible to prevent AIDS mortality and morbidity.
format Article
id doaj-art-917f421b96c14c64bde6999c034e3151
institution Kabale University
issn 1687-708X
1687-7098
language English
publishDate 2014-01-01
publisher Wiley
record_format Article
series Interdisciplinary Perspectives on Infectious Diseases
spelling doaj-art-917f421b96c14c64bde6999c034e31512025-02-03T07:26:02ZengWileyInterdisciplinary Perspectives on Infectious Diseases1687-708X1687-70982014-01-01201410.1155/2014/625670625670A Comparative Systematic Review of the Optimal CD4 Cell Count Threshold for HIV Treatment InitiationBabatunde Olubajo0Kathryn Mitchell-Fearon1Oluseye Ogunmoroti2Eastern Health Research and Analysis, Inc., 1 Press Place, Athens, GA 30601, USADepartment of Community Health and Psychiatry, The University of the West Indies, Mona, Kingston 7, JamaicaAtlanta English Institute, 4000 Dekalb Technology Parkway, Atlanta, GA 30340, USAHIV infection is no longer characterized by high morbidity, rapid progression to AIDS, and death as when the infection was first identified. While anti-retroviral drugs have improved the outcome of AIDS patients, clinical research on the appropriate time to initiate therapy continues to evolve. Optimal therapy initiation would maximize the benefits of these drugs, while minimizing side effects and drug resistance. Recent 2013 WHO guidelines changed HIV therapy initiation from 350 cells/μL to 500 cells/μL. This systematic review provides an evidence-based comparison of starting treatment at >500 cells/μL with starting treatment at the range between 350 cells/μL and 500 cells/μL. An 11% increase in risk was detected from initiation therapy at the 350–500 cells/μL range (0.37 [0.26, 0.53]), when compared with starting treatment before 500 cells/μL (0.33 [0.22, 0.48]). Most individual study comparisons showed a benefit for starting treatment at 500 cells/μL in comparison with starting at the 350–500 cells/μL range with risks ranging from 19% to 300%, though a number of comparisons were not statistically significant. Overall, the study provides evidence based support for initiating anti retroviral therapy at cell counts >500 cells/μL wherever possible to prevent AIDS mortality and morbidity.http://dx.doi.org/10.1155/2014/625670
spellingShingle Babatunde Olubajo
Kathryn Mitchell-Fearon
Oluseye Ogunmoroti
A Comparative Systematic Review of the Optimal CD4 Cell Count Threshold for HIV Treatment Initiation
Interdisciplinary Perspectives on Infectious Diseases
title A Comparative Systematic Review of the Optimal CD4 Cell Count Threshold for HIV Treatment Initiation
title_full A Comparative Systematic Review of the Optimal CD4 Cell Count Threshold for HIV Treatment Initiation
title_fullStr A Comparative Systematic Review of the Optimal CD4 Cell Count Threshold for HIV Treatment Initiation
title_full_unstemmed A Comparative Systematic Review of the Optimal CD4 Cell Count Threshold for HIV Treatment Initiation
title_short A Comparative Systematic Review of the Optimal CD4 Cell Count Threshold for HIV Treatment Initiation
title_sort comparative systematic review of the optimal cd4 cell count threshold for hiv treatment initiation
url http://dx.doi.org/10.1155/2014/625670
work_keys_str_mv AT babatundeolubajo acomparativesystematicreviewoftheoptimalcd4cellcountthresholdforhivtreatmentinitiation
AT kathrynmitchellfearon acomparativesystematicreviewoftheoptimalcd4cellcountthresholdforhivtreatmentinitiation
AT oluseyeogunmoroti acomparativesystematicreviewoftheoptimalcd4cellcountthresholdforhivtreatmentinitiation
AT babatundeolubajo comparativesystematicreviewoftheoptimalcd4cellcountthresholdforhivtreatmentinitiation
AT kathrynmitchellfearon comparativesystematicreviewoftheoptimalcd4cellcountthresholdforhivtreatmentinitiation
AT oluseyeogunmoroti comparativesystematicreviewoftheoptimalcd4cellcountthresholdforhivtreatmentinitiation